Q1 2025 Thyrocare Technologies Ltd Earnings Call Transcript
Key Points
- Thyrocare Technologies Ltd (BOM:539871) reported a 16% year-on-year revenue growth for Q1 FY25, driven primarily by the pathology business.
- The company has successfully implemented a slab-based pricing model, which has been well accepted by the franchisee network, leading to increased motivation and volume growth.
- 25 out of 30 NABL labs are now NABL accredited, with 94% of total sample load processed in these labs, showcasing a strong commitment to quality.
- The company processed 6 million samples and served 4 million patients in Q1 FY25, reflecting a 13% and 9% year-on-year growth in volume, respectively.
- Thyrocare Technologies Ltd (BOM:539871) has entered into a business transfer agreement to acquire Polo Labs Private Limited, expanding its footprint in North India.
- The EBITDA margin for the quarter decreased by 1 percentage point year-on-year, primarily due to increased material costs and foreign exchange fluctuations.
- Employee expenses have increased year-on-year due to annual increments and new business acquisitions, impacting overall profitability.
- The radiology business, despite showing some revenue growth, continues to contribute minimally to the bottom line, with significant maintenance costs due to old equipment.
- The company has seen a decline in realization per sample in the partnership business, attributed to the addition of lower-cost tests during sample collection.
- There is a long tail in the partnership business, with the top five partners contributing 50-60% of the revenue, indicating potential dependency on a few key partners.
Ladies and gentlemen, good day and welcome to Thyrocare Technologies Limited earnings conference call. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Kapil Gupta from Thyrocare Technologies Limited. Thank you and over to you.
Yeah. So thank you, Yashashree. A very good evening to all, and thank you for joining us today for the Thyrocare earnings conference call for the first-quarter FY25. Today, we have with us Mr. Rahul Guha, MD and CEO of Thyrocare; Mr. Alok Jagnani, CFO of Thyrocare; and Mr. Nitin Chugh, Chief Commercial Officer of Thyrocare, along with other key members of the senior management on this call to share highlights of the business and financials for the quarter.
I hope you have gone through our results and the quarterly earnings presentation, which has now been uploaded on the stock exchange website. The transcript of this call will be available in a week's time on the company's website.
Please note that today's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
